ICON Public Limited (NASDAQ:ICLR) Receives $243.33 Average Price Target from Analysts

Shares of ICON Public Limited (NASDAQ:ICLR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $232.67.

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group cut shares of ICON Public from a "buy" rating to a "neutral" rating and reduced their price target for the company from $250.00 to $200.00 in a research report on Friday, March 21st. Royal Bank of Canada restated an "outperform" rating and set a $263.00 price target on shares of ICON Public in a research note on Wednesday, January 15th. Citigroup reduced their price objective on ICON Public from $290.00 to $215.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Mizuho cut their target price on shares of ICON Public from $238.00 to $200.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Finally, JPMorgan Chase & Co. decreased their price target on shares of ICON Public from $280.00 to $265.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ICLR. Natixis Advisors LLC increased its stake in ICON Public by 6.7% in the 4th quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company's stock valued at $37,279,000 after purchasing an additional 11,177 shares in the last quarter. State of Tennessee Department of Treasury raised its position in ICON Public by 1.0% during the fourth quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company's stock worth $33,333,000 after acquiring an additional 1,600 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its position in shares of ICON Public by 40.6% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company's stock valued at $20,363,000 after purchasing an additional 28,050 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of ICON Public by 15,701.6% during the 1st quarter. GAMMA Investing LLC now owns 68,421 shares of the medical research company's stock worth $119,730,000 after purchasing an additional 67,988 shares in the last quarter. Finally, Motley Fool Wealth Management LLC raised its position in shares of ICON Public by 2.3% during the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company's stock worth $13,342,000 after purchasing an additional 1,466 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

ICON Public Stock Down 1.1 %

NASDAQ:ICLR traded down $1.58 during trading hours on Friday, hitting $145.16. The company's stock had a trading volume of 794,565 shares, compared to its average volume of 893,724. ICON Public has a 52-week low of $138.51 and a 52-week high of $347.72. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $11.72 billion, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 1.86 and a beta of 1.24. The stock has a fifty day moving average of $178.63 and a 200-day moving average of $209.35.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. On average, equities analysts forecast that ICON Public will post 13.38 earnings per share for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.